Decheng Capital LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002010850

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 11 positions · Total reported value $685.07M · Top-10 concentration 99.9% · Updated 2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

Turnover: 35.7% · 0 new · 2 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -3.5% · vs SPY -5.6% · Prev Value $731.75M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -13.4% · vs SPY -15.6% · Latest Value $685.07M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Decheng Capital LLC disclosed 11 equity positions with a combined reported value of $685.07M. The filing implies a focused portfolio: its ten largest positions account for 99.9% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were CGON ($451.69M), NUVB ($145.34M), ACRS ($21.26M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Decheng Capital LLC opened 0 new positions, trimmed 2 and fully exited 3, a turnover rate of 35.7% of positions. The portfolio's overlap with the prior quarter was 79% of names.

Of the 3 positions fully exited versus the prior quarter, the largest were RVMD ($9.86M), NAMS ($5.99M), TNGX ($625.20K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

No new positions this quarter.

Fully Exited (vs previous quarter)

  • RVMD REVOLUTION MEDICINES INC · prev qtr: $9.86M
  • NAMS NEWAMSTERDAM PHARMA COMPANY · prev qtr: $5.99M
  • TNGX TANGO THERAPEUTICS INC · prev qtr: $625.20K

Insider Transactions (Form 4)

Latest Decheng Capital LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Decheng Capital LLC, based in Menlo Park, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 14 positions worth $731.75M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: MENLO PARK, CA, United States
  • SEC registration: 801-118587 (status: Approved), registered 2020-04-30
  • Regulatory AUM (Form ADV): $2.73B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 8 private funds, of which 1 hedge funds
  • Website: decheng.com

Portfolio Structure

  • 14 positions · $731.75M reported value (Q2 2026)
  • Top 10 holdings = 98.1% of reported value
  • Largest position: CGON (CG ONCOLOGY INC) at 61.9%
  • Average position size: $52.27M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 3 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund maintains a concentrated, bullish stance on biotech/healthcare (100% sector exposure), with slight portfolio tightening (total value up modestly, positions unchanged). No new additions suggest conviction in existing holdings. 2. Key moves: - Reduced: RCUS (-8.5% shares, weight -0.36%), BYSI (-19.3% shares, weight -0.57%). - No additions (New: 0). 3. Portfolio structure: Highly active, concentrated (top-10 = 98.84% of AUM), biotech-focused (high-risk, high-reward). Minimal diversification implies aggressive growth/innation bets. 4. Per-holding one-liner: - CGON: Oncology drug developer (CG ONCOLOGY). - NUVB: Biotech firm (NUVATION BIO). - ACRS: Skin disease treatments (ACLARIS THERAPEUTICS). - AARD: Respiratory drug developer (AARDVARK THERAPEUTICS). - UPB: Cancer-focused biotech (UPSTREAM BIO). - RCUS: Oncology therapies (ARCUS BIOSCIENCES). - EQ: Autoimmune disease drugs (EQUILLIUM). - LYEL: Cancer immunotherapy (LYELL IMMUNOPHARMA). - ZNTL: Cancer drugs (ZENTALIS PHARMACEUTICALS). - BYSI: Cancer treatments (BEYONDSPRING). 5. Style summary: Concentrated biotech fund with selective trimming of underperformers, maintaining high conviction in clinical-stage oncology/therapeutics.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-16 16:33

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 6.37M $451.69M 65.93%
65.93%
Hold
2 25.95M $145.34M 21.22%
21.22%
Hold
3 4.04M $21.26M 3.10%
3.10%
Hold
4 3.92M $20.64M 3.01%
3.01%
Hold
5 2.72M $14.36M 2.10%
2.10%
Hold
6 425.08K $10.98M 1.60%
1.60%
Reduce
7 4.45M $7.23M 1.05%
1.05%
Hold
8 692.05K $6.78M 0.99%
0.99%
Hold
9 1.32M $3.67M 0.54%
0.54%
Hold
10 3.07M $2.36M 0.34%
0.34%
Reduce
11 326.81K $761.47K 0.11%
0.11%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 90% R 90% F1 90% (modelled on 2026-Q2; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 83% · recall 83% · F1 83% · avg rank error 1.7 · Top-10 turnover 20%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q2 70% 70% 70% ALPN · CGON · ZNTL · ILMN · BYSI · RCUS · KRYS · FDMT · EQ · PHAT CGON · NUVB · RCUS · ZNTL · KRYS · BYSI · ILMN · MRUS · PHAT · NAMS
2024-Q3 100% 100% 100% CGON · NUVB · RCUS · ZNTL · KRYS · MRUS · ILMN · BYSI · PHAT · NAMS CGON · NUVB · PHAT · RCUS · KRYS · ILMN · ZNTL · BYSI · NAMS · MRUS
2024-Q4 60% 60% 60% CGON · NUVB · PHAT · RCUS · KRYS · ILMN · ZNTL · BYSI · NAMS · MRUS CGON · NUVB · UPB · NAMS · ILMN · RCUS · KRYS · RVMD · HLXA · CRNX
2025-Q1 70% 70% 70% CGON · NUVB · UPB · NAMS · ILMN · KRYS · RCUS · RVMD · HLXA · CRNX CGON · NUVB · AARD · UPB · NAMS · KRYS · RVMD · MRUS · BYSI · HLXA
2025-Q2 90% 90% 90% CGON · NUVB · AARD · UPB · NAMS · KRYS · RVMD · MRUS · ACRS · BYSI CGON · AARD · NUVB · UPB · NAMS · BYSI · MRUS · KRYS · HLXA · RVMD
2025-Q3 80% 80% 80% CGON · AARD · NUVB · UPB · NAMS · BYSI · MRUS · KRYS · HLXA · RVMD CGON · NUVB · UPB · AARD · NAMS · MRUS · RVMD · LYEL · BYSI · ACRS
2025-Q4 80% 80% 80% CGON · NUVB · UPB · AARD · NAMS · MRUS · RVMD · LYEL · RCUS · BYSI CGON · NUVB · UPB · AARD · LYEL · NAMS · RVMD · RCUS · ACRS · EQ
2026-Q1 100% 100% 100% CGON · NUVB · UPB · AARD · LYEL · NAMS · RVMD · RCUS · ACRS · EQ CGON · NUVB · UPB · ACRS · AARD · LYEL · NAMS · RCUS · RVMD · EQ
2026-Q2 90% 90% 90% CGON · NUVB · UPB · ACRS · AARD · LYEL · RCUS · NAMS · EQ · RVMD CGON · NUVB · AARD · ACRS · UPB · RCUS · EQ · RVMD · LYEL · BYSI
2026-Q3 ★ 90% 90% 90% CGON · NUVB · AARD · ACRS · UPB · EQ · RCUS · LYEL · RVMD · BYSI CGON · NUVB · ACRS · AARD · UPB · RCUS · EQ · LYEL · ZNTL · BYSI

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Decheng Capital LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Decheng Capital LLC reported 11 equity positions worth $685.07M in aggregate; its largest disclosed positions were CGON ($451.69M), NUVB ($145.34M), ACRS ($21.26M).

How large is Decheng Capital LLC's portfolio?

Decheng Capital LLC reported $685.07M of long equity holdings across 11 positions as of 2026-Q3. Top-10 holdings account for 99.9% of reported value.

What is Decheng Capital LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/decheng-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →